AusperBio to Present AHB-137 Data at EASL Congress 2024

AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. (collectively known as AusperBio) have announced the forthcoming presentation of significant new clinical data concerning their HBV ASO molecule, AHB-137. This data will be shared through two late-breaking posters at the annual European Association for the Study of the Liver (EASL™) Congress 2024, scheduled from June 5th to 8th in Milan, Italy. These posters will provide insights from two Phase I clinical trials held both globally and in China, assessing AHB-137's safety, tolerability, pharmacokinetics, and preliminary effectiveness.

The specific details of the poster presentations are as follows:

1. Poster Title: Safety and antiviral activity of AHB-137, a novel antisense oligonucleotide, in healthy volunteers and subjects with chronic hepatitis B.
- Abstract #: LB249
- Poster #: LBP-019
- Session: Late breaker posters
- Date: Wednesday, June 5, 2024
- Time: Available from 8:30 a.m. CEST
- Presenter: Prof. Edward J. Gane, University of Auckland, New Zealand

2. Poster Title: A phase 1, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of AHB-137 in Chinese healthy volunteers and subjects with chronic hepatitis B.
- Abstract #: LB256
- Poster #: LBP-043
- Session: Late breaker posters
- Date: Wednesday, June 5, 2024
- Time: Available from 8:30 a.m. CEST
- Presenter: Wen Wang, The First Hospital of Jilin University, China

AHB-137 represents a novel unconjugated antisense oligonucleotide (ASO), which is a part of AusperBio's proprietary Med-Oligo™ ASO technology platform. This molecule has shown promising potential in preclinical studies, as highlighted during the 2023 EASL™ conference. The current Phase I trials are being conducted across multiple international centers as well as in China, where a Phase I/IIa trial is also in progress. This global development strategy is a significant step towards achieving a functional cure for chronic hepatitis B.

Chronic Hepatitis B (CHB) is a severe liver disease impacting approximately 290 million people worldwide. It can lead to severe complications such as cirrhosis and hepatocellular carcinoma. While existing treatment options can suppress the replication of the hepatitis B virus (HBV), achieving a definitive cure remains rare. Therefore, the discovery and development of a finite treatment for CHB are of paramount importance.

AusperBio, a clinical-stage biopharmaceutical company operating in the USA and China, focuses on advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial emphasis on curing chronic hepatitis B. The company’s Med-Oligo™ ASO platform introduces innovative designs and capabilities that significantly enhance the current ASO therapeutics landscape. This modular platform, combined with efficient targeted delivery conjugation technologies, aims to empower ASO therapeutics to treat a broad spectrum of conditions including viral infections, metabolic diseases, genetic disorders, and immune diseases.

AusperBio continues to leverage its expertise and technology to push forward the boundaries of medical science, with the ultimate goal of providing a functional cure for chronic hepatitis B and potentially other significant health conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!